News
BBOT
2.300
+12.75%
0.260
Weekly Report: what happened at BBOT last week (1102-1106)?
Weekly Report · 17h ago
Weekly Report: what happened at BBOT last week (1026-1030)?
Weekly Report · 11/02 10:20
Russell 2000 estimated to add 107 stocks in December rebalance - Stephens
Seeking Alpha · 10/29 19:12
Piper Sandler Remains a Buy on BridgeBio Oncology Therapeutics (BBOT)
TipRanks · 10/26 11:45
Weekly Report: what happened at BBOT last week (1019-1023)?
Weekly Report · 10/26 10:20
BridgeBio Oncology Thera Is Maintained at Overweight by Morgan Stanley
Dow Jones · 10/21 16:07
BridgeBio Oncology Thera Price Target Cut to $13.00/Share From $18.00 by Morgan Stanley
Dow Jones · 10/21 16:07
Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13
Benzinga · 10/21 15:58
BridgeBio Oncology Thera Is Maintained at Outperform by Oppenheimer
Dow Jones · 10/20 18:23
BridgeBio Oncology Thera Price Target Cut to $16.00/Share From $22.00 by Oppenheimer
Dow Jones · 10/20 18:23
Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16
Benzinga · 10/20 18:12
BridgeBio Oncology price target lowered to $16 from $22 at Oppenheimer
TipRanks · 10/20 11:45
BridgeBio Oncology: The KRAS Opportunity Hidden In The Selloff
Seeking Alpha · 10/19 12:22
Weekly Report: what happened at BBOT last week (1012-1016)?
Weekly Report · 10/19 10:20
Weekly Report: what happened at BBOT last week (1005-1009)?
Weekly Report · 10/12 10:26
Weekly Report: what happened at BBOT last week (0928-1002)?
Weekly Report · 10/05 10:25
Weekly Report: what happened at BBOT last week (0921-0925)?
Weekly Report · 09/28 10:20
Weekly Report: what happened at BBOT last week (0914-0918)?
Weekly Report · 09/21 10:20
10 small-cap U.S. healthcare stocks with the weakest momentum grades
Seeking Alpha · 09/18 14:20
Analysts’ Top Healthcare Picks: BridgeBio Oncology Therapeutics (BBOT), Entera Bio (ENTX)
TipRanks · 09/18 12:30
More
Webull provides a variety of real-time BBOT stock news. You can receive the latest news about BridgeBio Oncology Therapeutics, Inc through multiple platforms. This information may help you make smarter investment decisions.
About BBOT
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.